Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Accured ExpensesChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Gains from Investment Securities (2021 - 2025)

Historic Gains from Investment Securities for Bioadaptives (BDPT) over the last 3 years, with Q2 2025 value amounting to $500000.0.

  • Bioadaptives' Gains from Investment Securities changed N/A to $500000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $500000.0, marking a year-over-year change of. This contributed to the annual value of $90219.0 for FY2021, which is N/A changed from last year.
  • Per Bioadaptives' latest filing, its Gains from Investment Securities stood at $500000.0 for Q2 2025.
  • In the past 5 years, Bioadaptives' Gains from Investment Securities ranged from a high of $500000.0 in Q2 2025 and a low of -$272965.0 during Q4 2022
  • Its 3-year average for Gains from Investment Securities is $84317.0, with a median of $110210.0 in 2022.
  • Data for Bioadaptives' Gains from Investment Securities shows a peak YoY increase of 15420.97% (in 2022) and a maximum YoY decrease of 18976.87% (in 2022) over the last 5 years.
  • Bioadaptives' Gains from Investment Securities (Quarter) stood at -$94201.0 in 2021, then tumbled by 189.77% to -$272965.0 in 2022, then soared by 283.17% to $500000.0 in 2025.
  • Its Gains from Investment Securities was $500000.0 in Q2 2025, compared to -$272965.0 in Q4 2022 and $110210.0 in Q3 2022.